Why is staudinger ligation and transition metal catalysis less used in bioorthogonal drug delivery?
Best insight from top research papers
Staudinger ligation and transition metal catalysis are less used in bioorthogonal drug delivery due to challenges such as incomplete biocompatibility, slow kinetics, and limitations in biological media. While Staudinger ligation set a new paradigm for bioconjugation strategies, its incomplete biocompatibility hinders its widespread application. Transition metals, although versatile, face challenges in hostile biological environments, necessitating coordinating enzymes or stabilizing structures for in vivo use. Additionally, the slow kinetics and incomplete biocompatibility of these methods have led to the advancement of faster and more biocompatible bioorthogonal reactions like the inverse-electron demand Diels-Alder reaction, which offers ideal kinetics and biocompatibility for drug delivery applications. These limitations highlight the need for more efficient and biocompatible bioorthogonal reactions in drug delivery systems.
Answers from top 4 papers
More filters
| Papers (4) | Insight |
|---|---|
5 Citations | Staudinger ligation and transition metal catalysis are less used in bioorthogonal drug delivery due to solubility and substrate specificity challenges, requiring coordinating enzymes and stabilizing superstructures for in vivo applications. |
14 Citations | Staudinger ligation and transition metal catalysis are less used in bioorthogonal drug delivery due to challenges in achieving in situ catalysis within specific subcellular organelles like lysosomes. |
| Not addressed in the paper. | |
12 Citations | Transition metal catalysis is less used in bioorthogonal drug delivery due to limitations in biological media, despite its potential for abiotic reactions. Staudinger ligation may have similar challenges. |
Related Questions
How does albumin affects delivery of drug?4 answersAlbumin significantly impacts drug delivery by serving as a versatile carrier due to its biocompatibility and ability to bind various drugs. It forms nanoparticles that can actively target tumors, enhancing drug delivery to cancer cells. Albumin's interaction with drugs affects their efficacy, toxicity, distribution, and metabolism, ultimately influencing their pharmacological behavior. In the context of lung diseases, albumin-based nanocarriers offer advantages like low cost, nontoxicity, and high drug-loading capacity, making them effective in managing conditions like COPD, asthma, and lung cancer. By encapsulating drugs in albumin nanoparticles, targeted drug delivery systems can be developed for various therapeutic purposes, including anti-inflammatory and anti-thrombotic applications.
What are the potential implications of metal ions-mediated photolysis on the efficacy and safety of pharmaceutical drugs?5 answersMetal ions, such as copper(II), can modulate the photodegradation rate of pharmaceutical drugs. In the presence of copper(II), the photodegradation rate of the fluoroquinolone Rufloxacin decreases under aerobic conditions. However, in anaerobic media, the photodegradation rate of Rufloxacin increases with increasing copper(II) concentration. Metallopharmaceuticals, including metal complexes, have been investigated for their potential in antitumor therapy. Photochemical activation of metallopharmaceuticals offers the possibility to control the location, timing, and dosage of the therapeutic metal complex. Phototoxicity is a safety concern in pharmaceutical research, and structural modification of drug molecules can be utilized to mitigate this risk. Metallopharmaceuticals, such as iron chelating drugs, can undergo photolysis under UV irradiation, potentially affecting their efficacy and safety. These findings highlight the importance of considering metal ions-mediated photolysis in the development and evaluation of pharmaceutical drugs.
What are the interesting theories about bioorthonal catalysis mediated by palladium and single atom catalyst?4 answersBioorthogonal catalysis mediated by palladium and single atom catalysts has been the subject of interesting theories. One theory suggests that Mo-single-atom catalysts, synthesized through a facile approach, show remarkable activity and stability in the Co2+/3+(bpy)3 redox reaction. Another theory explores the doping of palladium (Pd) into gold clusters stabilized by poly(N-vinyl-2-pyrrolidone) (Au:PVP), which enhances catalytic activity for aerobic oxidation reactions. Additionally, an Al2O3-supported Pd single-atom catalyst has been found to exhibit higher activity and selectivity compared to Pd nanoparticles in the oxidation of cinnamyl alcohol. Furthermore, a single-atom Pd catalyst, prepared from nitrogen-doped graphene, has shown high acetylene conversion rate, ethylene selectivity, and stability in selective hydrogenation reactions. These theories highlight the potential of palladium and single atom catalysts in various catalytic reactions, offering new avenues for the design and development of high-activity catalysts.
What are the interesting theories about bioorthogonal catalysis mediated by palladium and single atom catalyst?3 answersBioorthogonal catalysis mediated by palladium and single atom catalysts has been the subject of interesting theories. One theory suggests that artificial metalloenzymes (ArMs) with peptide ligands carrying palladium complexes can simultaneously mediate two types of chemistry, enabling the synthesis of anticancer drugs in human cells. Another theory proposes the use of cancer-derived exosomes loaded with palladium catalysts as a targeted therapy for cancer cells, allowing for the selective delivery of catalysts into specific cell types. Additionally, a versatile light-controlled bioorthogonal catalyst has been developed by modifying silica-Pd0 with a supramolecular complex, allowing for the regulation of catalytic activity through light-induced structural changes. Furthermore, the doping of palladium into gold clusters has been shown to enhance catalytic activity, with single Pd atom doping improving the catalytic performance for aerobic oxidation and hydrogenation reactions. These theories highlight the potential of palladium and single atom catalysts in bioorthogonal catalysis.
How can we use catalysis to improve the efficiency of biological processes?5 answersBiocatalysis can be used to improve the efficiency of biological processes through various strategies. One approach is the modification of biocatalysts at the molecular level, such as through semi-rational design of enzyme molecules and intensification of substrate channelling. Another method is the engineering of intelligent microbial cell factories through metabolic engineering and synthetic biology, which allows for the optimization of whole cellular levels and the efficient production of various products. Synergistic interactions in microbial communities can also be utilized to engineer more complex and robust functions. Immobilization of enzymes is another technique that can enhance their properties and improve their efficiency. Additionally, protein engineering and other aspects of biocatalysis engineering, such as substrate, medium, and reactor engineering, can be employed to further improve the efficiency and sustainability of biocatalytic reactions. These advancements in biocatalysis offer opportunities for the development of new processes and the improvement of existing ones.
What are catalytic antibodies How are they important in the treatment of disease?10 answers